Jun 05, 2023 8:00 am EDT Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
May 25, 2023 4:00 pm EDT MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
May 25, 2023 8:00 am EDT MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
May 24, 2023 7:00 am EDT MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
May 17, 2023 4:01 pm EDT MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
May 04, 2023 4:02 pm EDT MindMed Reports First Quarter 2023 Financial Results and Business Highlights
May 02, 2023 8:00 am EDT MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
May 01, 2023 4:01 pm EDT MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update